Company Overview and News

4
REITs Are A Natural Hedge Against Trade Risk

2018-09-07 seekingalpha
But, if it were to escalate to a 'trade war', we believe commercial real estate would outperform traditional equities.
DRE CAT VNO.WI VNORP BXP AMT COR STAG VNO LXP FR PLD WPC REXR LPT BA SLG

 
Trump trade war with China spurs 'off the charts' rush at Port of LA

2018-08-15 cnbc
The escalating trade war with China is leading U.S. retailers to speed up the import of goods from Asia's largest economy to avoid new tariffs and ensure they have adequate supplies for the winter holidays.
DRE REXR

4
Rexford Industrial Realty (REXR) Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Greetings, and welcome to the Rexford Industrial Realty, Inc. Second Quarter 2018 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
WFC WFCNP REXR

154
10 High-Dividend Stocks to Buy When the Market Is Blue

2018-08-03 investorplace - 4
President Donald Trump ran on a ticket of making America great again. While the consensus on that point is very much split, what’s not deniable is the markets’ response. Trump’s pro-business agenda was credited with sparking an impressive rally. With enthusiasm overshooting rationality, however, high-dividend stocks have become very attractive to investors.
FB XOM TWX PSA.A VZA BAC AMZN PSAXZ MO MPW GE STR GEC D EFX TMUSP TMUS TWC PSA IRM S T QUSA VZ GNE REXR HPQ

7
Mid-Year REIT Market Update

2018-07-05 seekingalpha
Between the four REIT team members, we met with over 50 REIT management teams at the June REITWeek conference.
BPY DCT KRC BXP TCO KRG UDR LSI TRNO EQR MAC AVB VNO EQIX FR FRT JBGS RVI JCAP SPG QTS WPG PEI REG SKT CXP EXR CONE COR ESS GGP EGP DDR MNR ROIC UE RPAI PLD KRLP OFC IRT REXR DLR LPT WRI ESRT

24
Dividend Champions For July 2018

2018-07-02 seekingalpha
The Dividend Champions list is a monthly publication tracking companies with a history of consistently increasing their dividends. Wider in scope than the well-known S&P 500 Dividend Aristocrats and Nasdaq Dividend Achievers, the Dividend Champions covers all companies listed on exchanges in the United States. In order to be included in the list, the annual split-adjusted dividend payout of a company (based on calendar year) must be consistently increasing.
CQP TKR FITBI WMS CTRE FISI WEBK FIISO FIISP MDLZ MFC 0945 OLBK PRIM TTEK REXR MFC FITB

50
United Community Banks downgraded to hold vs. buy at SunTrust Robinson Humphrey

2018-06-26 marketwatch
KS Bancorp: Shareholders Should Reject The Proposal Of Conversion To Delaware Corporation And Pressure The Management For A Sale
SBNY SBNYW HOPE GPRE IEX UE.WI RHP ETH UBSH NFX UE HCKT DST IPGP UCBI REXR UNB RPM AKAM GHDX ECPG

 
REXR / Rexford Industrial Realty, Inc. 424B5 (Prospectus)

2018-06-13 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-210691 CALCULATION OF REGISTRATION FEE
REXR

 
REXR / Rexford Industrial Realty, Inc. FORM 8-K (Current Report)

2018-06-13 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
REXR

19
SA Interview: Investing In REITs With Robert Ruggirello, CFA

2018-06-10 seekingalpha
Robert Ruggirello, CFA is the Managing Director of Brave Eagle Wealth Management, a NY-based Registered Investment Advisor.
PLD TRNO SKT GPT AMH REXR GGP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...